- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03833882
Evaluation of MAF-1217 in Patients With DED
Evaluation of the Performance of the Tear Substitute MAF-1217 in Patients With Evaporative DED
This is a pre-market, multicentre, double-blind, randomized, crossover, non-inferiority study comparing the efficacy of MAF-1217 and Cationorm® in adult patients with evaporative DED.
The study population will be divided in 4 different subgroups, according to the different types of evaporative DED:
- Group A: high evaporative levels
- Group B: females in menopause, whether using hormonal integration or not
- Group C: presence of active obstructive Meibomian gland disease
- Group D: glaucomatous patients
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Patients will be enrolled after having signed the informed consent form prior any other study procedure and after inclusion/exclusion criteria check.
Each patient will be planned to perform 6 study visits and at each visit all necessary study procedures will be performed according to the clinical investigation plan requirements (see flow-chart).
The study visits will be performed at: screening, baseline, week 2, week 6, week 8, week 12.
Patients will be enrolled at screening visit and at baseline, after the wash-out period of 1 week, then will be randomized to receive MAF-1217 or Cationorm® for the following 6 weeks.
After this time lapse, patients will be switched to the opposite therapy for 6 additional weeks.
The entire study population will be asked for a TID posology, and will be divided in 4 different subgroups, according to the different types of evaporative DED.
Certain test will be performed only in some patients:
Osmolimetry and tear sampling in 20 patients(10/site) chosen random from groups B, C and D; Ferning test only in group D; tear film collection and cytokine expression only in 20 patients form site nr. 2.
Patients will be allowed to carry on any systemic or local medications, apart lubricating eyedrops, which have to be stopped the day before baseline visit.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Milan, Itálie, 20121
- Ospedale San Paolo, ASST Santi Paolo e Carlo
-
Milan, Itálie, 20157
- ASST Fatebenefratelli Sacco P.O.L. Sacco
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- At least 18 years old (adult patients), male and female
- Schirmer I test > 10 mm at 5'
- (Group A): high evaporative levels
- (Group B): females in menopause, both using hormonal integration or not
(Group C): presence of active obstructive Meibomian gland disease, defined as at least one of the following:
- Meibomian orifice plugging
- eyelid margin foaminess
- changes in orifice position with respect to the mucocutaneous junction
- abnormal Meibomian gland secretions (opaque and viscous-like form that is difficult to express)
- (Group D): glaucomatous patients receiving one or more BAK preserved treatments for at least 2 years, showing an abnormal Ferning test (Types 3 or 4 according to Rolando)
- all: wishing to participate in the study and able to sign the ICF
Inclusion criteria to be checked at baseline:
- BUT < 7"
- Mild to severe DED according to OSDI chart
Exclusion Criteria:
- Neuropathic causes of dry eye (diabetes, long-standing contact lens wearing, previous ocular herpes infections)
- Coexisting corneal diseases
- Autoimmune diseases
- Past or active cicatricial conjunctivitis
- Past ocular surface burns
- Keratinization of the eyelid margin
- Sjogren syndrome
- History of corneal trauma
- Pregnant and lactating women
- Younger than 18 years old patients
- Use of contact lenses
- inability to self administer study medications
- (GROUPS B, D) Presence of active obstructive Meibomian gland disease
- (GROUP C) Presence of cicatricial Meibomian gland disease
- known allergic sensitivity to any of the devices ingredients or any other known allergy
- participation in a clinical trial during the 3 months prior to the beginning of the study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Crossover Assignment
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: MAF1217/Cationorm
|
The study population will have to self-administer the study treatment in a TID posology.
The study population will have to self-administer the study treatment in a TID posology.
|
|
Experimentální: Cationorm/MAF1217
|
The study population will have to self-administer the study treatment in a TID posology.
The study population will have to self-administer the study treatment in a TID posology.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Break-up time (BUT) differences
Časové okno: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Changes in break-up time (BUT) versus baseline
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
ocular surface staining (corneal and conjunctival)
Časové okno: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in ocular surface staining (corneal and conjunctival)
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
Schirmer I test (ST) (without anesthesia)
Časové okno: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in Schirmer I test (ST) (without anesthesia)
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
number of blinking per minute
Časové okno: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in number of blinking per minute
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
Ferning test (Group D)
Časové okno: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in Ferning test (Group D)
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
osmolarity
Časové okno: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in osmolarity
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
patient satisfaction (10 points VAS scale)
Časové okno: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in patient satisfaction (10 points VAS scale). (VAS: scale where patient has to specify level of satisfaction by indicating a position along a continuous line between two end-points (0 - 10). 0 indicates no satisfaction while 10 represents the highest level). |
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
OSDI
Časové okno: measured at week 2, 6, 8 and 12 weeks treatment
|
Changes in questionnaire scores (OSDI - Ocular Surface Disease Index).
The overall Ocular Surface Disease score defined the ocular surface as normal (0-12 points) or as having mild (13-22 points), moderate (23-32 points), or severe (33-100 points) disease.
|
measured at week 2, 6, 8 and 12 weeks treatment
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- VF-OS-001/2018
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .